Changes in calcium metabolism and bone mineral density in new users of medroxyprogesterone acetate during the first year of use.
Body composition
Bone mineral density
Caffeine
Calcium metabolism
Contraception
Depot medroxyprogesterone acetate
Journal
International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics
ISSN: 1879-3479
Titre abrégé: Int J Gynaecol Obstet
Pays: United States
ID NLM: 0210174
Informations de publication
Date de publication:
Dec 2019
Dec 2019
Historique:
received:
09
01
2019
revised:
19
06
2019
accepted:
30
08
2019
pubmed:
4
9
2019
medline:
22
1
2020
entrez:
4
9
2019
Statut:
ppublish
Résumé
To evaluate calcium metabolism and bone mineral density (BMD) in new users of depot medroxyprogesterone acetate (DMPA) in the first year of use. This prospective, non-randomized study, conducted at the University of Campinas, São Paulo, Brazil, was carried out between February 2011 and February 2013. Women aged from 18 to 40 with a body mass index (BMI, calculated as weight in kilograms divided by the square of height in meters) <30 and with no known history of disease or medication use who chose to use DMPA were paired by age (±1 year) and BMI (±1) with women commencing the use of a copper intrauterine device (IUD). The primary outcomes were BMD measured by dual-energy X-ray absorptiometry and calcium metabolism markers; other variables were body composition and lifestyle habits. Repeated measures analysis of variance (ANOVA) and multiple regression analyses were used to evaluate associations. Twenty-seven women using DMPA and 24 using IUD were evaluated, with a mean age of 29.7 years and 28.6 years, respectively. The DMPA group presented with a 3.6% (P<0.001) loss of lumbar spine BMD, a 2.1% (P=0.100) loss of femoral neck BMD and higher phosphorus (P=0.014) concentrations at 12 months compared to the IUD group. The decreases in BMD were associated with the use of DMPA, while total mass and coffee intake were found to be protective factors. Changes in calcium metabolism and a decrease in BMD were found in the DMPA group at 12 months.
Substances chimiques
Contraceptive Agents, Female
0
Medroxyprogesterone Acetate
C2QI4IOI2G
Calcium
SY7Q814VUP
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
319-325Subventions
Organisme : Brazilian National Research Council (CNPq)
Organisme : The São Paulo Research Fundation (FAPESP)
Organisme : São Paulo State Health Department (SES-SP)
Informations de copyright
© 2019 International Federation of Gynecology and Obstetrics.
Références
Quintino-Moro A. Evaluation of thyroid hormone, bone mineral density and calcium metabolism in new users of the contraceptive depot medroxyprogesterone acetate during the first year of use of the method’. http://repositorio.unicamp.br/jspui/bitstream/REPOSIP/333905/1/Quintino-Moro_Alessandra_D.pdf. Accessed August 21, 2019.
World Health Organization. Medical eligibility criteria for contraceptive use, 5th edn. Geneva: WHO; 2015. http://apps.who.int/iris/bitstream/10665/181468/1/9789241549158_eng.pdf?ua=1. Accessed August 24, 2017.
Tang OS, Tang G, Yip P, Li B, Fan S. Long-term depot-medroxyprogesterone acetate and bone mineral density. Contraception. 1999;59:25-29.
Clark MK, Sowers MR, Nichols S, Levy B. Bone mineral density changes over two years in first-time users of depot medroxyprogesterone acetate. Fertil Steril. 2004;82:1580-1586.
Meier C, Brauchli YB, Jick SS, Kraenzlin ME, Meier CR. Use of depot medroxyprogesterone acetate and fracture risk. J Clin Endocrinol Metab. 2010;95:4909-4916.
Kyvernitakis I, Kostev K, Nassour T, Thomasius F, Hadji P. The impact of depot medroxyprogesterone acetate on fracture risk: A case-control study from the UK. Osteoporos Int. 2016;28:291-297.
Clark MK, Sowers M, Levy B, Nichols S. Bone mineral density loss and recovery during 48 months in first-time users of depot medroxyprogesterone acetate. Fertil Steril. 2006;86:1466-1474.
Rahman M, Berenson AB. Predictors of higher bone mineral density loss and use of depot medroxyprogesterone acetate. Obstet Gynecol. 2010;115:35-40.
Kaunitz AM, Miller PD, Rice VM, Ross D, McClung MR. Bone mineral density in women aged 25-35 years receiving depot medroxyprogesterone acetate: Recovery following discontinuation. Contraception. 2006;74:90-99.
Kaunitz AM, Arias R, McClung M. Bone mineral recovery after depot medroxyprogesterone acetate injectable contraception use. Contraception. 2008;77:67-76.
Gai L, Zhang J, Zhang H, Gai P, Zhou L, Liu Y. The effect of depot medroxyprogesterone acetate (DMPA) on bone mineral density (BMD) and evaluating changes in BMD after discontinuation of DMPA in Chinese women of reproductive age. Contraception. 2011;83:218-222.
Ott SM, Scholes D, Lacroix AX, Ichikawa LE, Yoshida CK, Barlow WE. Effects of contraceptive use on bone biochemical markers in young women. J Clin Endocrinol Metab. 2001;86:179-185.
Shaarawy M, El-Mallah SY, Seoudi S, Hassan M, Mohsen IA. Effects of the long-term use of depot medroxyprogesterone acetate as hormonal contraceptive on bone mineral density and biochemical markers of bone remodeling. Contraception. 2006;74:297-302.
Compston JE. Sex steroids and bone. Physiol Rev. 2001;2001(81):419-447.
Ishida Y, Ishida Y, Heersche JN. Pharmacologic doses of medroxyprogesterone may cause bone loss through glucocorticoid activity: An hypothesis. Osteoporos Int. 2002;13:601-605.
Dvornyk V, Liu XH, Shen H, et al. Differentiation of Caucasians and Chinese at bone mass candidate genes: Implication for ethnic difference of bone mass. Ann Hum Genet. 2003;67(Pt 3):216-227.
Hallstrom H, Wolk A, Glynn A, Michaëlsson K. Coffee, tea and caffeine consumption in relation to osteoporotic fracture risk in a cohort of Swedish women. Osteoporos Int. 2006;17:1055-1064.
Babatunde OO, Forsyth JJ. Association between depot medroxyprogesterone acetate (DMPA), physical activity and bone health. J Bone Miner Metab. 2014;32:305-311.
Harel Z, Wolter K, Gold MA, et al. Inadequate vitamin D status in adolescents with substantial bone mineral density loss during the use of depot medroxyprogesterone acetate injectable contraceptive: A pilot study. J Pediatr Adolesc Gynecol. 2010;23:209-214.
Ford ES, Kohl HW 3rd, Mokdad AH, Ajani UA. Sedentary behavior, physical activity, and the metabolic syndrome among U.S. adults. Obes Res. 2005;13:608-614.
Fisberg RM, Marchioni DM, Colucci AC. Assessment of food consumption and nutrient intake in clinical practice. Arq Bras Endocrinol Metabol. 2009;53:617-624.
Holick MF. Environmental factors that influence the cutaneous production of vitamin D. Am J Clin Nutr. 1995;61(3 Suppl):638S-645S.
Garber CE, Blissmer B, Deschenes MR, et al. Quantity and quality of exercise for developing and maintaining cardiorespiratory, musculoskeletal, and neuromotor fitness in apparently healthy adults: Guidance for prescribing exercise. Med Sci Sports Exerc. 2011;43:1334-1359.
Nejar KA, BenseñorI IM, Lotufo PA. Sunshine and suicide at the tropic of Capricorn, São Paulo, Brazil, 1996-2004. Rev Saude Publica. 2007;41:1062-1064.
Choi E, Choi KH, Park SM, Shin D, Joh HK, Cho E. The benefit of bone health by drinking coffee among Korean postmenopausal women: A cross-sectional analysis of the Fourth & Fifth Korea National Health and Nutrition Examination Surveys. PLoS ONE. 2016;27(11):e0147762.
Grimes DA, Schulz KF. Surrogate end points in women's health research: Science, protoscience, and pseudoscience. Fertil Steril. 2010;93:1731-1734.